Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Is Being Restructured by A Reverse Merger

GCDX and Uni-Pharma April 30, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113228108

Uni-Pharma Part 3 - Global Cancer Diagnostics Part 1
April 29, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113192928

Uni-Pharma Part 2 April 28, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113155567

Uni-Pharma Part 1 April 27, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113119285


Conclusion: April 26, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113104999

Part 1 April 20, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006


Part 2 April 21, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112930694


Part 3 April 22, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112973321

Part 4 April 23, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113014648

Part 5 April 24, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113056841

Part 6 April 25, 2015 Rebuttals

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113091753

All Roads Lead To Taipei,Taiwan Uni-Pharma Partnering with Global cancer Diagnostics to Manufacture and distribute Onko-Sure Overseas.


Runcoach Said:

"Clarification on Uni"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113195445

Runcoach Said:

"I see you offer not one shred of proof that Uni ever paid another royalty payment like you claimed and the SEC filing clearly shows the agreement is now null and void due to patent expiration."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113230916

Does one know if the June 6, 2013 agreement between Uni-Pharma and AMDL Diagnostics was renegotiated after the last patent expired? NO we don't know. We do know that Uni-Pharma still has an agreement with AMDL Diagnostics to manufacture and distribute Onko-Sure exclusively in Taiwan.Do we know if Uni-Pharma and their Manufacturing partner are manufacturing and selling to SRL Diagnostics and Metropolis Healthcare in India after the patent expired? Yes we know. Is Uni-Pharma advertising and distributing Onko-Sure after the last patent expired in the Bio Taiwan 2015.. Yes according to GSOK and the advertising of Onko-Sure by Uni-Pharma for the upcoming Bio Taiwan 2015. Do we know if Uni-Pharam has engaged in distributor agreements with Radient and AMDL Diagnostics in the past..Yes we know. Uni-Pharma engaged in a distributorship agreement in 2011 with AMDL Diagnostics Inc. and Radient in 2012. Do we know if the 2011 agreement in 2011 between Uni-Pharma and AMDL Diagnostics is still in force. Yes we know..Now we prove it you understand... Hope this will enlighten you.. Runcoach..After we present the facts .. Which agreement do you think is in force..The 2011 agreement between Uni-Pharma and AMDL Diagnostics Inc. or the June 3, 2013 agreement between Uni-Pharma and AMDL Diagnostics Inc? It is one or the other....


This is the PR from August 4, 2011. Radient/AMDL Diagnostics entered into an exclusive distribution agreement with Taiwan-based Uni Pharma, Co. Ltd. Uni Pharma will import, market, and sell Onko-Sure® in the Taiwanese market. It appears that it was Radient that entered into the agreement, we know now it was AMDL Diagnostics Inc. There was no SEC 8-K filing by Radient and no mention of the agreement in the 10-K ending December 31, 2011. If the agreement was with Radient there should have been an 8-K announcement and listed in the 10-K.


Radient Pharmaceuticals Enters Distribution Agreement With Uni Pharma for Onko-Sure Sales in Taiwan

8/4/2011

- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has entered into an exclusive distribution agreement with Taiwan-based Uni Pharma, Co. Ltd. Uni Pharma will import, market, and sell Onko-Sure® in the Taiwanese market.

http://www.devicespace.com/news_story.aspx?StoryID=229172

***************************************************************
Here is the 10-K from SEC filings for the year ending December 31, 2011. No mention of the Uni-Pharma exclusive agreement to distribute Onko-Sure in Taiwan.. Page 6 and 7 of the 10-K.

http://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm

As of December 31, 2011, we had entered into the following distribution agreements:


1. An exclusive five-year distribution agreement with Grifols USA, LLC (“Grifols”). This distribution agreement allows Grifols USA, LLC to market and sell Onko-Sure® for the monitoring of colorectal cancer to hospitals, clinical laboratories, clinics and other health care organizations in the U.S. and Puerto Rico.


2. Four distinct exclusive five-year distribution agreements, one three-year distribution agreement, and one two-year distribution agreement, with GenWay Biotech, Inc. (“GenWay”). These six distribution agreements allows Genway to market and sell Onko-Sure® for uses other than colorectal cancer to CLIA-certified laboratories in the U.S. as a lung cancer screen to laboratories in Canada, and the marketing and sales of Onko-Sure® in the United Kingdom, European Union, the Middle East, Russia and Greece.


3. An exclusive five-year distribution agreement with Pharmaline Saglik Hzmetleri Tic (“Pharmaline”). This distribution agreement allows Phamaline to market and sell Onko-Sure® in Turkey.


4. An exclusive five-year distribution agreement with Jaiva Guar Diagno (“Jaiva GD”). This distribution agreement allows Jaiva GD to market and sell Onko-Sure® in India.


5. An exclusive five-year distribution agreement with AMDL Australia PTY Ltd. (“AMDL Australia”). This distribution agreement allows AMDL Australia to market and sell Onko-Sure® in Australia and New Zealand.


6. An exclusive five-year distribution agreement with Phu Gia Trading Co. Ltd. (“Phu Gia”). This distribution agreement allows Phu Gia to market and sell Onko-Sure® in Vietnam, Laos, and Cambodia.


7. An exclusive five-year distribution agreement with Bio-Asia Diagnostics Co. Ltd. (“Bio-Asia”). This distribution agreement allows Bio-Asia to market and sell Onko-Sure® exclusively in Hong Kong and non-exclusively for research use only in China.


8. An exclusive five-year distribution agreement with Uni-Pharma Taiwan (“Uni-Pharma”). This distribution agreement allows Uni-Pharma to market and sell Onko-Sure® in Taiwan, Singapore, and Hong Kong/Macau.


9. An exclusive five-year distribution agreement with TS Pharm Inc. (“TS Pharm”). This distribution agreement allows TS Pharm to market and sell Onko-Sure® in Caribbean Region.


Page 7 of 132



10. A non-exclusive five-year distribution agreement with Omnimed Inc. (“Omnimed”). This distribution agreement allows Omnimed to market and sell Onko-Sure® in South Korea.


11. A non-exclusive five-year distribution agreement with Naroo Ditech Inc. (“Naroo”). This distribution agreement allows Naroo to market and sell Onko-Sure® in Korea.



In all of our exclusive distribution agreements, the distributor is required to purchase a minimum number of Onko-Sure® test kits during each quarter of the agreement to maintain their exclusivity rights in their assigned territories.



If minimum purchase requirements are not met, we maintain the right to convert the exclusive agreement into a non-exclusive agreement. The distributor is not legally bound to meet the minimums and in most cases, failure to meet the minimum does not constitute a breach of contract.



During the year ended December 31, 2011, our exclusive distributors did not meet the minimum purchase requirements.

We do know that Radient extended the agreement with Uni-Pharma

Radient expands distribution agreement with UniPharma

Radient Pharmaceuticals has expanded its Onko-Sure cancer test distribution agreement with UniPharma Taiwan.

As per the previous agreement, UniPharma had the exclusive right to distribute Radient's cancer test in Taiwan.

The expanded distribution agreement includes Singapore, Hong Kong and Macau.22 December 2011

http://contractservices.pharmaceutical-business-review.com/news/radient-expands-distribution-agreement-with-unipharma-221211


The agreement between Uni-Pharma and Radient in 2011 extended Uni-Pharma's exclusive territories to include Singapore, Honk Kong and Macau.According to the 10-K there was no mention of the agreement for exclusive rights to Taiwan in the 10-K. Where is that agreement? It was with AMDL Diagnostics Inc. and did not have to listed on the 10-K. According to the 10-K the extended agreement was nullified because Uni-Pharma did not meet the purchase requirements for Singapore, Honk Kong and Macau. There is once again no mention of Taiwan..Except in the 8-K on June 3, 2013 announcing the agreement between Uni-Pharma and AMDL Diagnostics Inc.

During the year ended December 31, 2011, our exclusive distributors did not meet the minimum purchase requirements.


8. An exclusive five-year distribution agreement with Uni-Pharma Taiwan (“Uni-Pharma”). This distribution agreement allows Uni-Pharma to market and sell Onko-Sure® in Taiwan, Singapore, and Hong Kong/Macau.


Here is the mentioning of the exclusive agreement that was still in force between AMDL Diagnostics and Uni-Pharma..Also the Macau territory was not included in the June 6, 2013 agreement..The only exclusive territory remained as Taiwan because the 2011 agreement between Uni-Pharma and AMDL Diagnostics Inc. was still enforced..If you notice in the June 3, 2013, there was no "Supercede Clause..Most agreements would include that clause if they wanted to make nullify the past agreement. This was not the case..


This License Agreement (the “Agreement”), which shall be effective as of June 6, 2013, is by and between Uni Pharma Co., Ltd., a Taipei, Taiwan limited liability company (“UNI”) and Radient Pharmaceuticals Corporation (including its subsidiary AMDL Diagnostics Inc.) a Delaware incorporated United States company (“RXPC”).

Whereas, UNI wishes to hold a non-exclusive 5 year license (excepting Taiwan which remains exclusive per UNI-RXPC exclusive distribution agreement) to RXPC’s Onko-Sure and DR-70 cancer blood test kits (the “Tests”), procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property identified in Exhibit A (the “Intellectual Property”).

The agreement covers the following territories: China, Hong Kong, Malaysia, Singapore, Indonesia, Thailand, Japan, India, Turkey and Australia and New Zealand. We also agreed not to issue exclusive rights to any other person(s) to sell the Tests in the covered territories during the term of the agreement.


From the June 3, 2013 agreement .Below means that Uni-Pharma still has an agreement in force. We have proved that this agreement was between Uni-Pharma and AMDL Diagnostics Inc.

(excepting Taiwan which remains exclusive per UNI-RXPC exclusive distribution agreement)

http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113_radientpharm.htm

The smoke screen continues..The patent was a diversion and conveniently was abandoned on June 16, 2014.

12-31-2014 Mail Abandonment for Failure to Respond to Office Action
12-29-2014 Aband. for Failure to Respond to O. A.
06-30-2014 Mail-Petition Decision - Granted
06-30-2014 Petition Decision - Granted
06-27-2014 Correspondence Address Change
06-24-2014 Electronic Review
06-23-2014 Petition Entered
06-24-2014 Email Notification
06-24-2014 Mail Final Rejection (PTOL - 326)
06-17-2014 Mail-Petition Decision - Dismissed
06-17-2014 Petition Decision - Dismissed
02-28-2013 Information Disclosure Statement considered
06-16-2014 Final Rejection
05-07-2014 Petition Entered
02-28-2013 Electronic Information Disclosure Statement
02-28-2013 Information Disclosure Statement (IDS) Filed
02-27-2013 Mail Interview Summary - Applicant Initiated - Telephonic
02-20-2013 Interview Summary- Applicant Initiated
02-20-2013 Interview Summary - Applicant Initiated - Telephonic
02-20-2013 Date Forwarded to Examiner
02-15-2013 Request for Continued Examination (RCE)


*****************************************************************
Provista Diagnostics applied for 3 new Trademarks and got the rights to use Videssa..It was abandoned and reapplied by Eli Lilly. Eli had Vydessa.

VIDESSA

2015-03-31 APPROVED FOR PUB - PRINCIPAL REGISTER
2015-04-21 ASSIGNED TO LIE
2015-04-27 LAW OFFICE PUBLICATION REVIEW COMPLETED

https://trademarks.justia.com/863/83/videssa-86383350.html

https://trademarks.justia.com/777/99/vydessa-77799007.html

https://trademarks.justia.com/860/99/vydessa-86099255.html

KLARIFYI

https://trademarks.justia.com/865/81/klarifyi-86581663.html

CLARENIDI

https://trademarks.justia.com/865/81/clarenidi-86581669.html

SENEPEA

https://trademarks.justia.com/865/81/senepea-86581643.html

******************************************************************

Page 65. This is the research done by provista diagnostics for the LC Sentinel Lung Cancer Test.


NOTE 3 — NOTE RECEIVABLE



On August 27, 2010, the Company advanced $95,000 to Provista Diagnostic, Inc. (“Provista”), as a note receivable. In addition, the note included $5,000 in origination fees. In connection with the note receivable agreement, Provista agreed to deliver two separate research reports to the Company by September 30, 2010 as full satisfaction of the balance owed. If the reports were not delivered to the Company by September 30, 2010, the agreement called for a 25% increase in the principal balance. Due to Provista’s failure to deliver such reports by September 30, 2010, the Company recorded interest income of $26,327, which represents the 25% increase from the principal balance of the note plus accrued interest of $1,062. If the research reports were not delivered to the Company by September 30, 2010, then the note required five equal payments of $20,000 (totaling $100,000) on the 1st day of each month commencing on the initial interest payment date (as defined in the note) and continuing thereafter until maturity (August 27, 2011). Interest accrued on the unpaid principal balance at a rate of 12% per annum until September 30, 2010. After this date, if the reports were not delivered interest began to accrue at the rate of 18% per annum.

http://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm

Page 111 10-K..April 30, 2015 has arrived..ahooooooooooooooooooo

Additionally, as part of the May 2012 Agreement and in order to provide for payment of past due legal fees, we issued to our legal counsel, Hunter Taubman Weiss LLP, a $300,000 unsecured 4% convertible note that matures on April 30, 2015, which shall (i) accrue interest at the rate of 4% per annum, (ii) be convertible into our Common Stock at a fixed conversion price of $0.01 per share, (iii) be subject to prepayment at the option of the Company, (iv) contain full ratchet and other customary anti-dilution protection, and (v) not be subject to any mandatory installment or other mandatory prepayment provisions prior to the April 30, 2015 maturity date.